Head-To-Head Survey: iBio (IBIO) versus The Competition

iBio (NYSE:IBIO) is one of 450 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare iBio to related businesses based on the strength of its valuation, dividends, analyst recommendations, institutional ownership, profitability, earnings and risk.

Risk & Volatility

iBio has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, iBio’s competitors have a beta of 10.55, meaning that their average stock price is 955% more volatile than the S&P 500.

Insider & Institutional Ownership

7.9% of iBio shares are owned by institutional investors. Comparatively, 39.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 0.6% of iBio shares are owned by insiders. Comparatively, 14.0% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for iBio and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	0	0	1	0	3.00
iBio Competitors	4780	9984	15977	364	2.38

iBio presently has a consensus target price of $5.00, indicating a potential upside of 458.91%. As a group, “Pharmaceutical preparations” companies have a potential upside of 214.49%. Given iBio’s stronger consensus rating and higher possible upside, equities research analysts plainly believe iBio is more favorable than its competitors.

Earnings & Valuation

This table compares iBio and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
iBio	$400,000.00	-$24.91 million	-0.51
iBio Competitors	$443.98 million	-$69.00 million	-8.95

iBio’s competitors have higher revenue, but lower earnings than iBio. iBio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares iBio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-73.15%	-45.51%
iBio Competitors	-2,610.01%	-412.87%	-44.50%

Summary

iBio beats its competitors on 7 of the 13 factors compared.

About iBio

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.